Eli Lilly & Co. has been making medicines for nearly 150 years. Our success continues to be deeply rooted in our purpose of making life better for all people — and we know we are better positioned to deliver scientific breakthroughs when our workplace is diverse, equitable and inclusive. What many people may not know […]
Pharma giant Eli Lilly (NYSE: LLY) has become an unstoppable stock to own lately. Year to date, its share price is up more than 50%. And despite trading at a hefty 130 times earnings, investors continue to buy up more shares of the company. Although it may seem like the stock is approaching a peak, […]
It can be hard to make the case that a stock which is trading at more than 120 times earnings is still a good buy, and that its growth prospects still look strong enough to justify its current valuation. But that’s what I’m going to try to do with Eli Lilly (NYSE: LLY) stock right […]
Eli Lilly (NYSE: LLY) shares have soared more than 87% over the past year, making this player look more like a growth stock than a slower-paced but steady pharmaceutical stock. Lilly sells a broad range of medicines, but what lately has struck the fancy of investors — and doctors and patients — is the company’s […]
One of the biggest contributors to growth in the pharmaceutical industry right now is weight-loss medicine. Diabetes and obesity treatments from Novo Nordisk, such as Ozempic, Rybelsus, and Wegovy, are taking the world by storm. Eli Lilly (NYSE: LLY) is another rising star in the weight loss arena thanks to blockbuster drug Mounjaro and the […]
(Bloomberg) — Eli Lilly & Co.’s relentless stock records have Morgan Stanley analysts musing whether it will become the first US company outside of the Magnificent Seven to reach a market value of $1 trillion. Most Read from Bloomberg The analysts lifted their price target on the weight-loss drugmaker to the highest on Wall Street […]
You may not expect a pharmaceutical stock to mimic the behavior of the latest hot growth stock and soar in the triple digits over 12 months. But Eli Lilly (NYSE: LLY) did it, climbing nearly 117% over the past year. This wasn’t just a random happening, but instead evidence investors are very excited about what’s […]
Eli Lilly (NYSE: LLY) had a very good year in 2023. Revenue jumped 20% and its stock skyrocketed 59%. The company also claimed the mantle as the world’s largest drugmaker by market cap. Will the momentum continue going forward? Probably. However, it won’t be as easy as some might think. Here are four reasons why […]